Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CGEN Stock Alerts

Compugen (CGEN) Competitors

Compugen logo
$2.72 +0.08 (+3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$2.74 +0.01 (+0.55%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CGEN vs. AKTS, SVRA, XERS, CVAC, and KALV

Should you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Aktis Oncology (AKTS), Savara (SVRA), Xeris Biopharma (XERS), CureVac (CVAC), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

How does Compugen compare to Aktis Oncology?

Compugen (NASDAQ:CGEN) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Compugen has a net margin of 48.57% compared to Aktis Oncology's net margin of 0.00%. Compugen's return on equity of 55.68% beat Aktis Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Compugen48.57% 55.68% 29.68%
Aktis Oncology N/A N/A N/A

Compugen presently has a consensus price target of $5.00, suggesting a potential upside of 83.82%. Aktis Oncology has a consensus price target of $32.00, suggesting a potential upside of 64.61%. Given Compugen's higher probable upside, analysts plainly believe Compugen is more favorable than Aktis Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compugen
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Aktis Oncology
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

12.2% of Compugen shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Compugen has higher revenue and earnings than Aktis Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$72.76M3.53$35.34M$0.377.35
Aktis Oncology$6.50M159.71N/AN/AN/A

In the previous week, Aktis Oncology had 4 more articles in the media than Compugen. MarketBeat recorded 6 mentions for Aktis Oncology and 2 mentions for Compugen. Compugen's average media sentiment score of 0.33 beat Aktis Oncology's score of 0.17 indicating that Compugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compugen
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Compugen beats Aktis Oncology on 8 of the 13 factors compared between the two stocks.

How does Compugen compare to Savara?

Savara (NASDAQ:SVRA) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Compugen has a net margin of 48.57% compared to Savara's net margin of 0.00%. Compugen's return on equity of 55.68% beat Savara's return on equity.

Company Net Margins Return on Equity Return on Assets
SavaraN/A -84.01% -63.60%
Compugen 48.57%55.68%29.68%

Savara presently has a consensus price target of $9.13, suggesting a potential upside of 73.81%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 83.82%. Given Compugen's higher probable upside, analysts plainly believe Compugen is more favorable than Savara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Savara
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Compugen
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

87.9% of Savara shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Savara has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.79, suggesting that its share price is 179% more volatile than the S&P 500.

Compugen has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SavaraN/AN/A-$118.84M-$0.53N/A
Compugen$72.76M3.53$35.34M$0.377.35

In the previous week, Compugen had 1 more articles in the media than Savara. MarketBeat recorded 2 mentions for Compugen and 1 mentions for Savara. Compugen's average media sentiment score of 0.33 beat Savara's score of 0.00 indicating that Compugen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Savara
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Compugen
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Compugen beats Savara on 11 of the 14 factors compared between the two stocks.

How does Compugen compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Xeris Biopharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500.

In the previous week, Xeris Biopharma had 3 more articles in the media than Compugen. MarketBeat recorded 5 mentions for Xeris Biopharma and 2 mentions for Compugen. Xeris Biopharma's average media sentiment score of 0.35 beat Compugen's score of 0.33 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Compugen
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Compugen has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$291.85M3.69$550K-$0.01N/A
Compugen$72.76M3.53$35.34M$0.377.35

Compugen has a net margin of 48.57% compared to Xeris Biopharma's net margin of 0.19%. Compugen's return on equity of 55.68% beat Xeris Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma0.19% -5.33% 0.16%
Compugen 48.57%55.68%29.68%

Xeris Biopharma currently has a consensus price target of $10.80, suggesting a potential upside of 73.35%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 83.82%. Given Compugen's stronger consensus rating and higher possible upside, analysts plainly believe Compugen is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Compugen
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Compugen beats Xeris Biopharma on 10 of the 16 factors compared between the two stocks.

How does Compugen compare to CureVac?

CureVac (NASDAQ:CVAC) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

CureVac has a net margin of 199.92% compared to Compugen's net margin of 48.57%. Compugen's return on equity of 55.68% beat CureVac's return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac199.92% -23.03% -19.09%
Compugen 48.57%55.68%29.68%

CureVac currently has a consensus price target of $6.83, suggesting a potential upside of 46.64%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 83.82%. Given Compugen's stronger consensus rating and higher possible upside, analysts plainly believe Compugen is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Compugen
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500.

In the previous week, Compugen had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Compugen and 0 mentions for CureVac. Compugen's average media sentiment score of 0.33 beat CureVac's score of 0.00 indicating that Compugen is being referred to more favorably in the news media.

Company Overall Sentiment
CureVac Neutral
Compugen Neutral

17.3% of CureVac shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CureVac has higher earnings, but lower revenue than Compugen. CureVac is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$70.74M14.78$175.50M$0.726.47
Compugen$72.76M3.53$35.34M$0.377.35

Summary

Compugen beats CureVac on 12 of the 17 factors compared between the two stocks.

How does Compugen compare to KalVista Pharmaceuticals?

Compugen (NASDAQ:CGEN) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Compugen has a net margin of 48.57% compared to KalVista Pharmaceuticals' net margin of 0.00%. Compugen's return on equity of 55.68% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Compugen48.57% 55.68% 29.68%
KalVista Pharmaceuticals N/A -214.88%-81.87%

Compugen currently has a consensus price target of $5.00, suggesting a potential upside of 83.82%. KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 14.56%. Given Compugen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Compugen is more favorable than KalVista Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compugen
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
KalVista Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22

Compugen has a beta of 2.79, suggesting that its share price is 179% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.

In the previous week, KalVista Pharmaceuticals had 33 more articles in the media than Compugen. MarketBeat recorded 35 mentions for KalVista Pharmaceuticals and 2 mentions for Compugen. Compugen's average media sentiment score of 0.33 beat KalVista Pharmaceuticals' score of -0.19 indicating that Compugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compugen
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
KalVista Pharmaceuticals
4 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Neutral

12.2% of Compugen shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Compugen has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$72.76M3.53$35.34M$0.377.35
KalVista Pharmaceuticals$49.08M27.87-$109.52M-$3.95N/A

Summary

Compugen beats KalVista Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGEN vs. The Competition

Export
MetricCompugenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$249.62M$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio7.1438.8529.0428.48
Price / Sales3.53157.28477.1060.43
Price / Cash7.0657.8827.6236.52
Price / Book2.507.039.676.67
Net Income$35.34M$23.62M$3.55B$332.64M
7 Day Performance-0.37%3.67%1.70%2.01%
1 Month Performance20.35%7.17%5.62%9.19%
1 Year Performance98.54%67.04%34.42%39.59%

Compugen Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGEN
Compugen
3.6183 of 5 stars		$2.72
+3.0%		$5.00
+83.8%		N/A$249.62M$72.76M7.1470
AKTS
Aktis Oncology
1.7834 of 5 stars		$19.72
-1.9%		$32.00
+62.3%		N/A$1.07B$6.50MN/A76
SVRA
Savara
1.7338 of 5 stars		$5.21
+0.9%		$9.13
+75.3%		N/A$1.06BN/AN/A20
XERS
Xeris Biopharma
3.1148 of 5 stars		$6.08
-0.7%		$10.80
+77.8%		N/A$1.05B$291.85MN/A290
CVAC
CureVac
N/A$4.66
flat		$6.83
+46.6%		N/A$1.05B$70.74M6.47880

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel